Table 3. Demographics, primary tumor features, and clinical outcomes of melanoma patients with TP53 or BRAFNon-V600 mutations.
| Variable | All (N=926) | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| TP53 mutant | ND TP53 | P value | BRAFNon-V600 mutant | ND BRAFNon-V600 | P value | |
| No. of Patients (%) | 180 (19.4%) | 746 (80.6%) | 60 (6.5%) | 866 (93.5%) | ||
| Median Age (range) | 58 (12-89) | 56 (13-94) | 0.019 | 60 (29-89) | 56 (12-94) | 0.005 |
| Gender (%) | 0.052 | 0.88 | ||||
| Male | 132 (21.2%) | 492 (78.8%) | 41 (6.6%) | 583 (93.4%) | ||
| Female | 48 (15.9%) | 254 (84.1%) | 19 (6.3%) | 283 (93.7%) | ||
| Primary site (%) | 0.0001 | 0.38 | ||||
| Trunk | 54 (15.9%) | 285 (84.1%) | 21 (6.2%) | 318 (93.8%) | ||
| Extremity | 38 (14.8%) | 218 (85.2%) | 12 (4.7%) | 244 (95.3%) | ||
| Head and neck | 87 (27.4%) | 230 (72.6%) | 26 (8.2%) | 291 (91.8%) | ||
| Other | 1 (7.1%) | 13 (92.9%) | 1 (7.1%) | 13 (92.9%) | ||
| Breslow thickness (mean) | 3.31mm | 3.35mm | 0.9 | 2.9mm | 3.38mm | 0.32 |
| Ulceration (%) | 0.9 | 0.63 | ||||
| Yes | 47 (18.7%) | 205 (81.3%) | 18 (7.1%) | 234 (92.9%) | ||
| No | 80 (19.2%) | 337 (80.8%) | 25 (6.0%) | 392 (94.0%) | ||
| Not available | 53 (20.6%) | 204 (79.4%) | 17 (6.6%) | 240 (93.4%) | ||
|
| ||||||
| Patients with stage IV | N=531 | |||||
|
| ||||||
| No. of Patients (%) | 107 (20.1%) | 424 (79.9%) | 41 (7.7%) | 490 (92.3%) | ||
| M stage (%) | 0.5 | 0.56 | ||||
| M1a | 5 (15.2%) | 28 (84.8%) | 1 (3.0%) | 32 (97.0%) | ||
| M1b | 22 (23.9%) | 70 (76.1%) | 8 (8.7%) | 84 (91.3%) | ||
| M1c | 80 (19.7%) | 326 (80.3%) | 32 (7.9%) | 374 (92.1%) | ||
| LDH at stage IV | 0.6 | 0.3 | ||||
| Elevated (%) | 57 (19.3%) | 239 (80.7%) | 26 (8.8%) | 270 (91.2%) | ||
| WNL (%) | 46 (20.4%) | 180 (79.6%) | 14 (5.9%) | 212 (94.1%) | ||
| Missing (%) | 4 (44.4%) | 5 (55.6%) | 1 (11.1%) | 8 (88.9%) | ||
|
| ||||||
| Patients with stage IV (tested within 12 mo) | N=417 | |||||
|
| ||||||
| Median OS from stage IV (Months, 95% CI) | 18.8 (14.0-23.6) | 15.3 (13.4-17.2) | 0.039 | 17.9 (14.7-17.9) | 16.1 (14.3-17.9) | 0.53 |
CI: confidence interval, LDH: lactate dehydrogenase, No.: Number, OS: overall survival, WNL: within normal limit, ND: not detected mutation